Advisors Asset Management Inc. Has $119,000 Stock Position in Cellebrite DI Ltd. $CLBT

Advisors Asset Management Inc. grew its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 24.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,133 shares of the company’s stock after purchasing an additional 1,214 shares during the quarter. Advisors Asset Management Inc.’s holdings in Cellebrite DI were worth $119,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Teacher Retirement System of Texas lifted its stake in shares of Cellebrite DI by 121.3% in the 1st quarter. Teacher Retirement System of Texas now owns 44,407 shares of the company’s stock valued at $863,000 after purchasing an additional 24,337 shares during the period. California State Teachers Retirement System lifted its stake in shares of Cellebrite DI by 19.3% in the 4th quarter. California State Teachers Retirement System now owns 71,385 shares of the company’s stock valued at $1,573,000 after purchasing an additional 11,555 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Cellebrite DI in the 1st quarter valued at $269,000. Bank of America Corp DE lifted its stake in shares of Cellebrite DI by 32.0% in the 4th quarter. Bank of America Corp DE now owns 680,375 shares of the company’s stock valued at $14,989,000 after purchasing an additional 165,116 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Cellebrite DI by 32.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 148,132 shares of the company’s stock valued at $3,263,000 after purchasing an additional 36,341 shares during the period. Institutional investors and hedge funds own 45.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on CLBT shares. Needham & Company LLC dropped their price objective on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, August 14th. Wall Street Zen downgraded Cellebrite DI from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Lake Street Capital dropped their price objective on Cellebrite DI from $24.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday, August 15th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $22.40.

Cellebrite DI Trading Down 2.2%

CLBT stock opened at $16.80 on Friday. The stock has a 50-day moving average price of $15.18 and a two-hundred day moving average price of $16.97. The stock has a market cap of $4.02 billion, a PE ratio of -22.11, a price-to-earnings-growth ratio of 3.12 and a beta of 1.28. Cellebrite DI Ltd. has a 1 year low of $13.10 and a 1 year high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.01. The firm had revenue of $113.28 million during the quarter, compared to analysts’ expectations of $112.33 million. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The company’s revenue was up 18.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.